-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
HAVN Life Enters Distribution Agreement With Mycrodose Therapeutics For U.S. Market
HAVN Life Enters Distribution Agreement With Mycrodose Therapeutics For U.S. Market
HAVN Life Sciences Inc. (CSE:HAVN) (OTC:HAVLF) (FSE: 5NP), a biotechnology company working with psychedelic compounds for investigational research to support brain health and cognitive function, announced on Thursday its entry into an exclusive U.S. Distribution Agreement with California-based Mycrodose Therapeutics Inc., a leading pharmaceutical company specializing in the research and development of advanced drug delivery systems utilizing DEA Schedule I, II and III substances and other compounds aimed at treating cancer-related conditions, mental health, and cognitive degenerative diseases.
The agreement will facilitate the import of HAVN Life's naturally derived GMP psilocybin to research institutions and researchers within the U.S. "at competitive prices" to alleviate "supply chain issues," reported HAVN in a press release.
"HAVN Life is kicking off 2022 with strong partnerships in both our research and retail divisions, and we are very excited to start fulfilling purchase orders for our research customers with our new U.S. distribution partner, Mycrodose Therapeutics," said HAVN Life CEO, Tim Moore. "We've been working closely with Chad and his team, and are excited about the potential of this partnership."
In December 2021, Mycrodose added a Schedule I Import license, which allows the import of psilocybin and psilocin for clinical trials, research and development, analytical purposes and distribution.
"Our company's proven ability to navigate the meticulous details required for approval by the DEA and FDA for these very difficult licenses has directly contributed to Mycrodose's ability to lead the U.S.-Pharmaceutical sector," stated Chad Conner, CEO of Mycrodose Therapeutics. "This distribution partnership with HAVN Life increases access and the ease of obtaining GMP psilocybin for any U.S.-based research institution, university, or private biotech company."
According to HVN, "the interest and demand for psilocybin research in the United States have grown significantly in 2021 and continue to outpace supply in 2022."
The firm noted that the DEA Increased the quota for psilocybin research in the U.S. Meanwhile HAVN and Mycrodose, have completed the first purchase order and delivery of naturally derived GMP raw psilocybin mushrooms from Jamaica into the United States.
Image By Ilona Szentivanyi.
HAVN Life Sciences Inc. (CSE:HAVN) (OTC:HAVLF) (FSE: 5NP), a biotechnology company working with psychedelic compounds for investigational research to support brain health and cognitive function, announced on Thursday its entry into an exclusive U.S. Distribution Agreement with California-based Mycrodose Therapeutics Inc., a leading pharmaceutical company specializing in the research and development of advanced drug delivery systems utilizing DEA Schedule I, II and III substances and other compounds aimed at treating cancer-related conditions, mental health, and cognitive degenerative diseases.
HAVN生命科學公司。(CSE:HAVN)(場外交易代碼:HAVLF)(FSE:5NP)是一家生物技術公司,致力於研究迷幻化合物以支持大腦健康和認知功能,該公司週四宣佈與總部位於加利福尼亞州的公司簽訂獨家美國分銷協議麥克羅劑量治療公司。是一家領先的製藥公司,專門研究和開發先進的藥物輸送系統,利用DEA附表I、II和III物質和其他化合物,旨在治療癌症相關疾病、精神健康和認知退行性疾病。
The agreement will facilitate the import of HAVN Life's naturally derived GMP psilocybin to research institutions and researchers within the U.S. "at competitive prices" to alleviate "supply chain issues," reported HAVN in a press release.
HAVN在一份新聞稿中報道,這項協議將促進HAVN Life天然提取的GMP裸蓋菇素“以具有競爭力的價格”進口到美國境內的研究機構和研究人員,以緩解“供應鏈問題”。
"HAVN Life is kicking off 2022 with strong partnerships in both our research and retail divisions, and we are very excited to start fulfilling purchase orders for our research customers with our new U.S. distribution partner, Mycrodose Therapeutics," said HAVN Life CEO, Tim Moore. "We've been working closely with Chad and his team, and are excited about the potential of this partnership."
HAVN Life首席執行官説:“2022年伊始,HAVN Life在我們的研究和零售部門都建立了強有力的合作伙伴關係,我們非常高興能與我們新的美國分銷合作伙伴Mycroose Treeutics一起為我們的研究客户完成採購訂單,”HAVN Life首席執行官説:“HAVN Life在我們的研究和零售部門都有強大的合作伙伴關係。蒂姆·摩爾。“我們一直在與乍得和他的團隊密切合作,並對這種夥伴關係的潛力感到興奮。”
In December 2021, Mycrodose added a Schedule I Import license, which allows the import of psilocybin and psilocin for clinical trials, research and development, analytical purposes and distribution.
2021年12月,麥克羅糖增加了附表一進口許可證,允許進口裸蓋菇素和裸蓋菇素用於臨牀試驗、研發、分析目的和分銷。
"Our company's proven ability to navigate the meticulous details required for approval by the DEA and FDA for these very difficult licenses has directly contributed to Mycrodose's ability to lead the U.S.-Pharmaceutical sector," stated Chad Conner, CEO of Mycrodose Therapeutics. "This distribution partnership with HAVN Life increases access and the ease of obtaining GMP psilocybin for any U.S.-based research institution, university, or private biotech company."
他説:“我們公司被證明有能力駕馭DEA和FDA批准這些非常困難的許可證所需的細緻細節,這直接促成了麥克羅糖領導美國製藥行業的能力。”查德·康納麥克羅劑量治療公司的首席執行官。與HAVN Life的這一經銷夥伴關係增加了任何總部設在美國的研究機構、大學或私營生物技術公司獲得GMP裸蓋菇素的機會和便利性。“
According to HVN, "the interest and demand for psilocybin research in the United States have grown significantly in 2021 and continue to outpace supply in 2022."
據HVN報道,“美國對裸蓋菇素研究的興趣和需求在2021年大幅增長,並在2022年繼續超過供應。”
The firm noted that the DEA Increased the quota for psilocybin research in the U.S. Meanwhile HAVN and Mycrodose, have completed the first purchase order and delivery of naturally derived GMP raw psilocybin mushrooms from Jamaica into the United States.
該公司指出,DEA增加了美國裸蓋菇素研究的配額。與此同時,HAVN和Mycrodde已經完成了從牙買加向美國運送天然GMP生裸蓋菌素蘑菇的第一筆訂單和交貨。
Image By Ilona Szentivanyi.
圖片由Ilona Szentivanyi拍攝。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧